ImmunoPrecise Antibodies Ltd.

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Immunoprecise Antibodies Financial Results and Business Highlights Earnings Call for the full fiscal year 2021. At this time, all participants are in a listen-only mode. Following the presentation, we will answer pre-submitted questions. If anyone has any difficulties hearing the conference, please press the star key followed by zero for operator assistance at any time. I would like to remind everyone that this conference call is being recorded today, Wednesday, July 28, 2021, at 430 p.m. Eastern Time. I will now turn the call over to John. John, please go ahead.

Thank you and welcome. Dr. Jennifer Bath, President and Chief Executive Officer of Immunoprecise Antibodies, and Ms. Lisa Hebling, Chief Financial Officer, will be the speakers on today's call. A Q&A period answering pre-submitted questions will follow their earnings report, followed by closing remarks. Before Dr. Beth begins, I have been asked by Immunoprecise Antibodies to read the following safe harbor regarding forward-looking statements. I would like to remind everyone that Immunoprecise's remarks today contain forward-looking statements about its current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or other future events or developments. In preparing these forward-looking statements, several assumptions were made by Immunoprecise, and there are risks that results actually obtained by the company will differ materially from those statements. As a consequence, the company cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. Immunoprecise refers current and potential investors to the forward-looking information section of its management discussion and analysis issued today at www.immunoprecise.com. cedar.com and on Egger at www.sec.gov. Forward-looking statements represent ImmunoPrecise's expectations as of July 28, 2021. Except as may be required by securities laws, ImmunoPrecise does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. I would now like to turn the conference call over to Dr. Bass.

Great. Thank you, John. And good afternoon, everyone.